Avidity Biosciences, INC 8-K filings

Avidity Biosciences reported positive initial results from its EXPLORE44 trial, showing significant improvements in key biomarkers for Duchenne muscular dystrophy patients treated with delpacibart zotadirsen.

Avidity Biosciences held its 2024 Annual Meeting on June 13, 2024, electing three Class I directors and ratifying the appointment of BDO USA, P.C. as its independent auditor.

Avidity Biosciences has priced a public offering of 10,550,000 shares of common stock at $38.00 per share, expecting gross proceeds of $400.9 million.

Avidity Biosciences reported significant reductions in DUX4 regulated genes and positive trends in functional improvements in its Phase 1/2 trial for FSHD, while also increasing the number of shares available under its incentive plan.

Avidity Biosciences has appointed Simona Skerjanec, a seasoned pharmaceutical executive, to its Board of Directors, effective May 14, 2024.

Avidity Biosciences announced its first quarter 2024 financial results, highlighted by a strong cash position and progress in clinical trials for its RNA therapeutics.

Avidity Biosciences reported positive long-term data from the MARINA-OLE trial showing reversal of disease progression in patients with myotonic dystrophy type 1 (DM1) and announced plans to initiate a Phase 3 trial in the second quarter of 2024.

Avidity Biosciences has successfully raised approximately $400 million through an oversubscribed private placement to fund its clinical-stage product development and extend its operational runway into late 2026.

Avidity Biosciences announces its fourth quarter and year-end 2023 financial results, highlighting progress in clinical programs and a strong cash position.